Insulin-induced vascular endothelial growth factor expression in retina

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 13, 1999, Pages 3281-3286

  Lu, Ming ^a,b   Amano, Shiro ^a,b,c   Miyamoto, Kazuaki ^a,b   Garland, Rebecca ^a   Keough, Karen ^a   Qin, Wenying ^a,b   Adamis, Anthony P ^a,b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HORMONAL REGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; RAT; RETINOPATHY; TRANSCRIPTION REGULATION;

ANIMALS; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; IN SITU HYBRIDIZATION; INSULIN; LYMPHOKINES; MALE; PIGMENT EPITHELIUM OF EYE; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL GANGLION CELLS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032720262     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1:200-204.
3. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med. 1984;311:365-372.
4. Lauritzen T, Frost-Larsen K, Larsen HW, et al. Two-year experience with subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes. 1985;34:74-79.
5. Dahl-Jorgenson K, Brinchmann-Hansen O, Hanssen KF, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin-dependent diabetes mellitus the Oslo study. BMJ. 1985;290:811-815.
6. The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. JAMA. 1988;260:37-41.
7. Brinchmann-Hansen O, Dahl-Jorgenson K, Sandvick L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ. 1992; 304:19-22.
8. Agardh C-D, Eckert B, Agardh E. Irreversible progression of severe retinopathy in voting type 1 diabetic patients after improved metabolic control. J Diabetes Complications. 1992;6:96-100.
9. Moskalets E, Galstyan G, Starostina E, Antsiferov M, Chantelau E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Dibetes Complications. 1994;8:45-50.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995; 13:36-51.
11. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:324-309.
12. Roysarkar TK, Gupta A, Dash RJ, et al. Effect of insulin therapy on progression of retinopathy in non-insulin-dependent diabetes mellitus. Am J Ophthalmol. 1993;115:569-574.
13. Henricsson M, Janzon L, Groop L. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. Diabetes Care. 1995;18:1571-1576.
14. Savage S, Estacio RO, Jeffers B, Schrier RW. Increased complications in non insulin dependent diabetic patients treated with insulin versus oral hyperglycemic agents: a population study. Proc Assoc Am Physicians. 1997;109:181-189.
15. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med. 1997;14: 123-131.
16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
17. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-107.
18. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
19. Ferrara N, Houck KA, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-31.
20. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44:98-103.
21. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
22. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovasculurization in a primate. Arch Ophthalmol. 1996;114:66-71.
23. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
24. Tolentino, MJ, Miller JW, Gragoudas ES, et al. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103: 1820-1828.
25. Tolentino MT, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol. 1996;114:964-970.
26. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
27. Adamis AP, Miller JW, Bernal M, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
28. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
29. Malecaze, F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476-1482.
30. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
31. Murata, T. Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
32. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40:726-30.
33. Fox CH. In situ hybridization for detection of HIV RNA. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York: Wiley; 1993.
34. Chomczynski P, Sacchi N. Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
35. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
36. Shima D, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol Med. 1995;2:182-193.
37. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46:1619-1626.
38. Shweiki D, Neeman M, Itkin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA. 1995;92:768-772.
39. Tilton RG, Kawamura T, Chang KC, et al. Vascular dysfunction induced by elevated glucose levels in nits is mediated by vascular endothelial growth factor. J Clin Invest. 1997;99:2192-2202.
40. Williams B, Gallacher, Patel H, Orme C. Glucose-induced protein kinase C activation regulates VPF mRNA expression and peptide production by human smooth muscle cells in vitro. Diabetes. 1997;46:1497-1503.
41. Yamagishi S, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem. 1997;272:8723-8730.
42. Lee T-S, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na, K)-adenosine triphosphate activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest. 1989;83:90-94.
43. Frank RN. The aldose reductase controversy. Diabetes. 1994;43: 169-172.
44. Pal S, Claffey KP, Cohen HT, et al. Activation of SP1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem. 1998;273:26277-26280.
45. Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med. 1997;3:879-886.
46. Frank RN, Amin R, Kennedy A, Hohman TC. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol. 1997;115:1036-1047.
47. Li W, Liu X, He Z, Yanoff M, Jian B, Ye X. Expression of apoptosis regulatory genes by retinal pericytes after rapid glucose reduction. Invest Ophthalmol Vis Sci. 1998;39:1535-1543.
48. Zelzer E, Levy Y, Kahana C, et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 1998;17:5085-5094.
49. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res. 1998;58:4008-4014.
50. Warren RS, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996;271:29483-29488.